| |OCTOBER 20269GSK HIBSAGO BECOMES FIRST ASO APPROVED FOR CHRONIC HEPATITIS BCAN INDIA'S NEOVII-VINS DEAL STRENGTHEN IMMUNOGLOBULIN MANUFACTURING?BAJAJ HEALTHCARE Q2 RESULTS: PROFIT JUMPS 27%, REVENUE RISES 19%SUN PHARMA'S $355M ACQUISITION UNLOXCYT HITS PREFERRED STATUSFAKE MEDICINE BILLING EXPOSES GAPS IN INDIA'S DRUG SUPPLY CHAINHibsago becomes the first ASO approved for chronic hepatitis B, giving patients a new option to control the virus after stopping treatment. The U.S. Food and Drug Administration clears the British drugmaker's therapy, chemically known as bepirovirsen, marking a milestone for people living with the liver infection. GSK positions the medicine as a key growth driver under new CEO Luke Miels, with expected peak annual sales exceeding £2 billion.The approval comes as the company races to launch innovative medicines ahead of patent losses in its HIV portfolio and targets more than £40 billion in annual revenue by 2031. Hibsago already holds approval in Japan and faces reviews in China and Europe. The U.S. Food and Drug Administration announces approval of GSK's hepatitis B drug Hibsago on Tuesday. The agency recognizes bepirovirsen as the first FDA-approved antisense oligonucleotide for chronic hepatitis B. POIndia's immunoglobulin manufacturing capabilities could gain a boost through a proposed collaboration between German biotechnology company Neovii Biotech GmbH and Indian biopharmaceutical firm VINS Bioproducts Ltd. The partnership centers on specialized biological products used in organ transplantation and the treatment of certain blood disorders.With technology transfer to India included in the proposed arrangement, the development raises an important question: could international collaboration help strengthen domestic production of critical biological medicines and improve access to specialized treatments? The Embassy of India in Berlin has facilitated the exchange of a non-disclosure agreement (NDA) between Neovii Biotech and VINS Bioproducts, paving the way for discussions on manufacturing, technology transfer and commercialization of immunoglobulin products in India. POBajaj Healthcare Q2 Results for FY27 show strong growth in revenue and profitability, supported by rising API exports and formulations sales. The pharmaceutical company reported an 18.9% year-on-year (YoY) increase in revenue from operations to Rs. 175.9 crore in the quarter ended September 30, 2026. Profit after tax (PAT) rose 26.9% to Rs. 14.1 crore, while EBITDA increased 12.2% to Rs. 32.1 crore.Unloxcyt hits preferred status after Sun Pharma's $355M acquisition strengthens its role in advanced skin cancer care. The therapy now carries a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who cannot undergo curative surgery or radiation.This upgrade adds to the Category 2A designation for metastatic disease granted in 2025 and rests on solid pivotal trial results that show durable responses plus a favorable safety profile. Sun Pharma advances its cutaneous Fake medicine billing is emerging as a critical concern for India's pharmaceutical supply chain, following a crackdown by Uttar Pradesh's Food Safety and Drug Administration (FSDA) in Lucknow's Aminabad medicine market. Licenses of 14 establishments were cancelled by the UP FSDA and those of 29 others were suspended.The investigation raises a question over how pharma transactions are verified when invoices record transactions that never involved any physical movement of medicines. Beyond the immediate enforcement action, the case highlights the importance of distributor accountability, reliable inventory records and stronger mechanisms to establish the authenticity and traceability of pharmaceutical products. POoncology presence as clinicians gain confidence in this first-and-only FDA-approved PD-L1-blocking antibody for advanced CSCC. The recognition further supports patient access by shaping payer policies and clinical pathways. POThe company also reported improved profit margins during the quarter. Its EBITDA margin reached 18.2%, up from 17.8% in Q1 FY27. The PAT margin rose to 8% from 7.5% in the corresponding quarter last year. Gross profit increased 12.4% YoY to Rs. 85.4 crore, while the gross margin remained steady at 48.3%. API exports emerged as a major growth driver for Bajaj Healthcare in Q2 FY27. Export sales climbed 28.5% YoY to Rs. 62.6 crore, compared with Rs. 48.7 crore in Q2 FY26. Exports also increased 25.1% sequentially. PO
< Page 8 | Page 10 >